ArticleMolecular oncology2026
Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease.
Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cachexia, a severe muscle-wasting syndrome, lacks objective biomarkers for early detection. This study aimed to identify circulating microRNA signatures for cachexia and cancer in senior dogs, a comparative oncology model for human disease. Serum microRNA expression was quantified in a cohort of 25 dogs, clinically classified by cachexia and cancer status. We identified a distinct signature for cachexia, with significant downregulation of miR-15a, miR-15b, miR-16, and miR-140. Circulating miR-16 emerged as the most robust individual biomarker for cachexia (AUC = 0.899). Furthermore, a sex-specific analysis revealed that miR-140 was significantly lower in female dogs with cancer compared to noncancer controls (P = 0.045), consistent with a sex- and disease-specific dual suppression mechanism involving estrogen receptor signaling and cachexia-driven systemic inflammation (corrected AUC = 0.667). These findings suggest circulating microRNAs as promising, noninvasive biomarkers for canine cachexia and highlight miR-140 as a candidate sex-specific biomarker for female cancers, warranting validation in larger cohorts. This work reinforces the value of the domestic dog as a spontaneous model for translational biomarker discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.